Yuichiro Semba

Yuichiro Semba

Auto-generated profile, based on publicly available information

Yuichiro Semba

Division of Precision Medicine, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 July 2023 in Blood Advances
Verified
Journal Article
Open access
PDF file
YKYoshikane Kikushige
Yoshikane Kikushige
TMToshihiro Miyamoto
Toshihiro Miyamoto
YKYu Kochi
Yu Kochi
YSYuichiro Semba
Yuichiro Semba
MOMaki Ohishi
Maki Ohishi
KAKoichi Akashi
Koichi Akashi
Cancer-specific metabolic activities play a crucial role in the pathogenesis of human malignancies. To investigate human acute leukemia–specific metabolic properties, we comprehensively measured the cellular metabolites within the CD34+ fraction of normal hematopoietic stem progenitor cells (HSPCs), primary human acute myelogenous leukemia (AML), and acute lymphoblastic leukemia (ALL) cells. Here, we show that human leukemia cells are addicted to the branched-chain amino acid (BCAA) metabolism to maintain their stemness, irrespective of myeloid or lymphoid types. Human primary acute leukemias had BCAA transporters for BCAA uptake, cellular BCAA, α-ketoglutarate (α-KG), and cytoplasmic BCAA transaminase-1 (BCAT1) at significantly higher levels than control HSPCs. Isotope-tracing experiments showed that in primary leukemia cells, BCAT1 actively catabolizes BCAA using α-KG into branched-chain α-ketoacids, whose metabolic processes provide leukemia cells with critical substrates for the trichloroacetic acid cycle and the synthesis of nonessential amino acids, both of which reproduce α-KG to maintain its cellular level. In xenogeneic transplantation experiments, deprivation of BCAA from daily diet strongly inhibited expansion, engraftment and self-renewal of human acute leukemia cells. Inhibition of BCAA catabolism in primary AML or ALL cells specifically inactivates the function of the polycomb repressive complex 2, an epigenetic regulator for stem cell signatures, by inhibiting the transcription of PRC components, such as zeste homolog 2 and embryonic ectoderm development. Accordingly, BCAA catabolism plays an important role in the maintenance of stemness in primary human AML and ALL, and molecules related to the BCAA metabolism pathway should be critical targets for acute leukemia treatment.

3 February 2022 in Blood
Verified
Journal Article
Closed access
PDF file
KSKensuke Sasaki
Kensuke Sasaki
TYTakuji Yamauchi
Takuji Yamauchi
YSYuichiro Semba
Yuichiro Semba
JNJumpei Nogami
Jumpei Nogami
HIHiroshi Imanaga
Hiroshi Imanaga
TMTakahiro Maeda
Takahiro Maeda
Acute lymphoblastic leukemia (ALL) harboring the IgH-CRLF2 rearrangement (IgH-CRLF2-r) exhibits poor clinical outcomes and is the most common subtype of Philadelphia chromosome-like acute lymphoblastic leukemia (Ph-like ALL). While multiple chemotherapeutic regimens, including ruxolitinib monotherapy and/or its combination with chemotherapy, are being tested, their efficacy is reportedly limited. To identify molecules/pathways relevant for IgH-CRLF2-r ALL pathogenesis, we performed genome-wide CRISPR-Cas9 dropout screens in the presence or absence of ruxolitinib using 2 IgH-CRLF2-r ALL lines that differ in RAS mutational status. To do so, we employed a baboon envelope pseudotyped lentiviral vector system, which enabled, for the first time, highly efficient transduction of human B cells. While single-guide RNAs (sgRNAs) targeting CRLF2, IL7RA, or JAK1/2 significantly affected cell fitness in both lines, those targeting STAT5A, STAT5B, or STAT3 did not, suggesting that STAT signaling is largely dispensable for IgH-CRLF2-r ALL cell survival. We show that regulators of RAS signaling are critical for cell fitness and ruxolitinib sensitivity and that CRKL depletion enhances ruxolitinib sensitivity in RAS wild-type (WT) cells. Gilteritinib, a pan-tyrosine kinase inhibitor that blocks CRKL phosphorylation, effectively killed RAS WT IgH-CRLF2-r ALL cells in vitro and in vivo, either alone or combined with ruxolitinib. We further show that combining gilteritinib with trametinib, a MEK1/2 inhibitor, is an effective means to target IgH-CRLF2-r ALL cells regardless of RAS mutational status. Our study delineates molecules/pathways relevant for CRLF2-r ALL pathogenesis and could suggest rationally designed combination therapies appropriate for disease subtypes.

9 February 2022 in Cancer Letters
Verified
Journal Article
Closed access
MIMamoru Ito
Mamoru Ito
MNMichitaka Nakano
Michitaka Nakano
HAHiroshi Ariyama
Hiroshi Ariyama
KYKyoko Yamaguchi
Kyoko Yamaguchi
RTRisa Tanaka
Risa Tanaka
KAKoichi Akashi
Koichi Akashi

30 April 2024 in Blood Neoplasia
Verified
Journal Article
Open access
HIHiroshi Imanaga
Hiroshi Imanaga
YSYuichiro Semba
Yuichiro Semba
KSKensuke Sasaki
Kensuke Sasaki
KSKiyoko Setoguchi
Kiyoko Setoguchi
HMHillary Maniriho
Hillary Maniriho
TMTakahiro Maeda
Takahiro Maeda
• Genome-wide CRISPR/Cas9 screens identify the mTORC1 pathway as crucial for B-ALL cell sensitivity to dexamethasone. • Dexamethasone transcriptionally regulates factors upstream of mTORC1 signaling, inducing cell death.

12 February 2026 in Blood
Verified
Journal Article
Open access
GKGentaro Kawano
Gentaro Kawano
RIRiichiro Ikeda
Riichiro Ikeda
DIDaisuke Ishihara
Daisuke Ishihara
TSTakahiro Shima
Takahiro Shima
TSTeppei Sakoda
Teppei Sakoda
YKYoshikane Kikushige
Yoshikane Kikushige
Therapy resistance in acute myeloid leukemia (AML) remains a major clinical obstacle, particularly because of the persistence of leukemia stem cells (LSC) capable of metabolic adaptation. Although venetoclax (Ven) inhibits oxidative phosphorylation (OXPHOS), we found that Ven-resistant LSC undergo glycolytic reprogramming to bypass OXPHOS inhibition. This metabolic shift is supported by enhanced ribosome biogenesis, which is sustained by upregulated de novo guanine nucleotide biosynthesis. Abundant guanine nucleotides suppress the impaired ribosome biogenesis checkpoint (IRBC), leading to TP53 destabilization and persistent MYC expression. The inhibition of inosine monophosphate dehydrogenases (IMPDH1/2) depletes guanine nucleotides, activates IRBC, stabilizes TP53, represses MYC, and impairs the metabolic shift to glycolysis. This metabolic rewiring disrupts LSC stemness and suppresses the reconstitution of human AML cells in xenotransplantation experiments. Notably, the suppression of LSC stemness was observed regardless of Ven resistance or the TP53 mutational status of AML cells. These findings reveal that mutation-independent TP53 inactivation is involved in resistant AML and suggest that targeting guanine nucleotide biosynthesis may offer a clinically actionable strategy to eradicate therapy-resistant LSC.

5 February 2026 in Blood
Verified
Journal Article
Closed access
YSYuichiro Semba
Yuichiro Semba
TYTakuji Yamauchi
Takuji Yamauchi
DBDaniel E. Bauer
Daniel E. Bauer
SOSeishi Ogawa
Seishi Ogawa
KAKoichi Akashi
Koichi Akashi
TMTakahiro Maeda
Takahiro Maeda
Acute myeloid leukemia (AML) with TP53 mutations is almost universally refractory to chemotherapy, molecular-targeted therapies, and hematopoietic stem cell transplantation, leading to dismal clinical outcomes. The lack of effective treatments underscores the urgent need for novel therapeutic strategies. Using genome-wide CRISPR/Cas9 dropout screens in isogenic Trp53–wild-type (WT) and Trp53-knockout mouse AML models, combined with transcriptomic and proteomic analyses of AML samples from mice and humans, we identify the XPO7-NPAT (exportin 7–nuclear protein, coactivator of histone transcription) pathway as essential for TP53-mutated AML cell survival. In TP53-WT AML, XPO7 functions as a tumor suppressor by regulating the nuclear abundance of p53 protein, particularly when basal levels of functional p53 are high. However, in TP53-mutated AML, XPO7 drives leukemia proliferation by retaining NPAT, an XPO7-associated protein predominantly expressed in TP53-mutated AML, within the nucleus. NPAT depletion induces genome-wide histone loss, compromises genomic integrity, and triggers replication catastrophe in TP53-mutated AML cells. Notably, the analysis of publicly available AML data sets, primary AML samples, and single-cell intrapatient mRNA profiles further reveals elevated XPO7 and NPAT expression in TP53-mutated AML. Finally, we validate the XPO7-NPAT pathway as a critical driver of leukemia progression in vivo using patient-derived xenograft models of TP53-WT and TP53-mutant AML. Our study delineates key molecular mechanisms underlying TP53-mutated AML pathogenesis and identifies the XPO7-NPAT axis as a critical vulnerability in this refractory leukemia subtype.